ERYTHROCYTE ANTIOXIDANT ENZYME-ACTIVITY IN CMF TREATED BREAST-CANCER PATIENTS

Citation
S. Subramaniam et al., ERYTHROCYTE ANTIOXIDANT ENZYME-ACTIVITY IN CMF TREATED BREAST-CANCER PATIENTS, Cancer biochemistry biophysics, 14(3), 1994, pp. 177-182
Citations number
24
Categorie Soggetti
Biology,Oncology,Biophysics
ISSN journal
03057232
Volume
14
Issue
3
Year of publication
1994
Pages
177 - 182
Database
ISI
SICI code
0305-7232(1994)14:3<177:EAEICT>2.0.ZU;2-4
Abstract
Most of breast cancer patients are treated with CMF, which is a combin ation of three anticancer agents, cyclophosphamide, methotrexate and 5 -fluorouracil. Metabolites of CMF induce lipid peroxidation by inactiv ating the antioxidant enzymes, thereby rendering the system inefficien t in management of the free radical aback. Acrolein and phosphoramide mustard are the metabolites of cyclophosphamide which are among the ca usative agents which reduce the activity of superoxide dismultase, cat alase, glutathione peroxidase, glutathione reductase, glutathione-S-tr ansferase and glucosed-6-phosphate dehydrogenase in erythrocytes of CM F treated breast cancer patients.